Aurobindo Pharma receives approval for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets

27 Sep 2012 Evaluate

Aurobindo Pharma has received tentative approval from the US Food & Drug Administration for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15mg (base)/500mg and 15mg (base)/850mg (ANDA 200823). The product will be eligible for final approval upon the expiration of 180-day generic drug exclusivity.

Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15mg (base)/500mg and 15mg (base)/850mg are the generic equivalent of Takeda Global Research Development Center Inc’s Actoplus Met Tablets, 15mg (base)/500mg and 15mg (base)/850mg. Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate. The product has a market size of approximately $ 433 Million for the twelve months ending March 2012 according to IMS.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India

The company now has a total of 159 ANDA approvals (134 Final approvals including 1 from Aurolife Pharma LLC and 25 tentative approvals) from USFDA

Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.

Aurobindo Pharma Share Price

1227.45 7.25 (0.59%)
22-Nov-2024 10:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1781.95
Dr. Reddys Lab 1200.20
Cipla 1487.35
Lupin 2056.40
Zydus Lifesciences 946.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.